Immunosuppression regimen and latitude impact keratinocyte carcinoma risk in US liver transplant recipients

被引:0
|
作者
Rosenthal, Benjamin E. [1 ]
Schaubel, Douglas E. [2 ]
Lewis, James D. [2 ,3 ]
Margolis, David J. [2 ,4 ]
Goldberg, David S. [5 ]
Bittermann, Therese [2 ,3 ,6 ]
机构
[1] Univ Penn, Dept Med, Philadelphia, PA USA
[2] Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA
[4] Univ Penn, Perelman Sch Med, Dept Dermatol, Philadelphia, PA USA
[5] Univ Miami, Dept Med, Miller Sch Med, Div Digest Hlth & Liver Dis, Miami, FL USA
[6] Hosp Univ Penn, Penn Transplant Inst, Dulles 2, 3400 Spruce St, Philadelphia, PA 19104 USA
关键词
Liver transplantation; Immunosuppression; Latitude; Keratinocyte carcinoma; NONMELANOMA SKIN-CANCER; SQUAMOUS-CELL CARCINOMA; KIDNEY; ASSOCIATION; POPULATION; QUEENSLAND; MANAGEMENT; INHIBITORS;
D O I
10.1007/s00403-024-03404-3
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Immunosuppression after solid organ transplantation is associated with an increased risk of keratinocyte carcinoma (KC). Despite its established morbidity, KC risk in liver transplant (LT) recipients is understudied, including the contribution of immunosuppression regimen and latitude. A retrospective cohort of 9,966 adult first LT alone recipients alive with their native allograft at 1-year post-LT without prior KC between 2007 and 2016 were identified using linked data from the Organ Procurement and Transplantation Network and Medicare administrative claims. The primary exposures were immunosuppression regimen and latitude of residence. The primary outcome was incident, de novo KC occurring at least 1-year after LT. Adjusted Cox regression analysis stratified by transplant center was used in all analyses. The cohort was 63.4% male, 70.2% White and with median age 61 years (interquartile range, IQR, 54-66) at transplant. Calcineurin inhibitor (CNI) with anti-metabolite combination was independently associated with incident KC when measured as intention-to-treat (adjusted hazard ratio (aHR) 1.21 vs. CNI monotherapy, 95% CI 1.02-1.43, p = 0.026), in a time-updating as-treated analysis (aHR 1.61, 95% CI 1.34-1.93; p < 0.001) and when measured as cumulative exposure (aHR 1.13 per 6-month increase, 95% CI: 1.02-1.33; p = 0.027). More southern latitude of residence was also independently associated with incident KC with an aHR of 1.26 per 5 degrees N decrease towards the Equator (95% CI: 1.08-1.47, p = 0.003). We demonstrate independent effects of CNI with antiM immunosuppression regimen and latitude of residence on the risk of post-LT KC, which will better inform screening practices and immunosuppression management.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients
    Locke, Jayme E.
    Singer, Andrew L.
    HEPATIC MEDICINE-EVIDENCE AND RESEARCH, 2011, 3 : 53 - 62
  • [2] Strategies of Immunosuppression for Liver Transplant Recipients With Hepatocellular Carcinoma
    Castroagudin, J. F.
    Molina-Perez, E.
    Ferreiro-Iglesias, R.
    Varo-Perez, E.
    TRANSPLANTATION PROCEEDINGS, 2011, 43 (03) : 711 - 713
  • [3] Belatacept Immunosuppression in High Risk Liver Transplant Recipients
    Masters, Brian M.
    Sparkes, Tracy M.
    Hanish, Steven I.
    Potosky, Darryn R.
    Hutson, William R.
    Barth, Rolf N.
    LaMattina, John C.
    TRANSPLANTATION, 2015, 99 : 275 - 276
  • [4] Do surveillance liver biopsies alter the immunosuppression regimen in pediatric liver transplant recipients?
    Jones, Danielle
    Cousino, David
    Vikraman, Deepak
    Mavis, Alisha
    PEDIATRIC TRANSPLANTATION, 2022, 26
  • [5] Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
    Hussaarts, Koen G. A. M.
    van Doorn, Leni
    Bins, Sander
    Sprengers, Dave
    de Bruijn, Peter
    van Leeuwen, Roelof W. F.
    Koolen, Stijn L. W.
    van Gelder, Teun
    Mathijssen, Ron H. J.
    PHARMACEUTICALS, 2021, 14 (01) : 1 - 10
  • [6] Immunosuppression Regimen and Risk of Posttransplant Diabetes Among Older Kidney Transplant Recipients
    Lentine, K.
    Ahn, J.
    Demarco, M. McAdams
    Xiao, H.
    Bunnapradist, S.
    Segev, D.
    Axelrod, D.
    Bae, S.
    Dharnidharka, V.
    Caliskan, Y.
    Chang, S.
    Hess, G.
    Snyder, J.
    Schnitzler, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 683 - 684
  • [7] IMMUNOSUPPRESSION WITH SIROLIMUS INCREASES CARDIOVASCULAR RISK IN LIVER TRANSPLANT RECIPIENTS
    Doycheva, I. B.
    Couto, C. A.
    Gelape, C. L.
    Kish, J. K.
    Martin, P.
    Levy, C.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S82 - S82
  • [8] Weaning of immunosuppression in liver transplant recipients
    Mazariegos, GV
    Reyes, J
    Marino, IR
    Demetris, AJ
    Flynn, B
    Irish, W
    McMichael, J
    Fung, JJ
    Starzl, TE
    TRANSPLANTATION, 1997, 63 (02) : 243 - 249
  • [9] IMMUNOSUPPRESSION MINIMIZATION IN LIVER TRANSPLANT RECIPIENTS
    Mucha, Krzysztof
    Foroncewicz, Bartosz
    Lerut, Jan
    Moszczuk, Barbara
    Florczak, Michal
    Perkowska, Agnieszka
    Krata, Natalia
    Zagozdzon, Radoslaw
    Urbanowicz, Arkadiusz
    Kniola, Emilia
    Zieniewicz, Krzysztof
    Paczek, Leszek
    TRANSPLANT INTERNATIONAL, 2019, 32 : 386 - 387
  • [10] Immunosuppression for older liver transplant recipients
    De Simone, Paolo
    Battistella, Sara
    Lai, Quirino
    Ducci, Juri
    D'Arcangelo, Francesca
    Marchetti, Piero
    Russo, Francesco Paolo
    Burra, Patrizia
    TRANSPLANTATION REVIEWS, 2024, 38 (01)